Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and α-difluoromethylornithine on tumorigenesis in a rat surgical model

被引:45
作者
Chen, XX
Li, N
Wang, S
Hong, JG
Fang, MZ
Yousselfsson, J
Yang, PY
Newman, RA
Lubet, RA
Yang, CS
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[3] NCI, Chemprevent Branch, Div Canc Prevent, Rockville, MD 20852 USA
关键词
D O I
10.1093/carcin/23.12.2095
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human esophageal adenocarcinoma (EAC) develops in a sequence from gastroesophageal reflux disease (GERD), columnar-lined esophagus (CLE), dysplasia, and eventually to EAC. We established a rat surgical EAC model with esophagogastroduodenal anastomosis (EGDA) to mimic the staged process of esophageal adenocarcinogenesis. Profiling of the AA metabolites with mass spectrometry showed that prostaglandin E2 (PGE2), leukotriene B4 (LTB4), 15-hydroeicosatetraenoic acid (HETE), 12-HETE, 8-HETE and 5-HETE all increased at the esophagoduodenal junction after EGDA as compared with the proximal esophagus, with PGE2 as the major metabolite. Consistent with this profile, cyclooxygenase 2 (Cox2) was overexpressed in the basal cell layer of esophageal squamous epithelium, CLE cells and EAC tumor cells of the EGDA rats, as compared with the normal esophageal epithelium. Sulindac (a Cox inhibitor), nordihydroguaiaretic acid (NDGA, a lipoxygenase inhibitor) and alpha-difluoromethylornithine (DFMO, an ornithine decarboxylase inhibitor) were tested for their possible inhibitory actions against the formation of EAC in the rat EGDA model. In a short-term study (for 4 weeks after surgery), dietary administration of both sulindac (300 and 600 p.p.m.) and NDGA (100 p.p.m.) effectively reduced the EGDA-induced inflammation. In a long-term chemoprevention study (for 40 weeks after surgery), 300 p.p.m. sulindac, alone or in combination with 100 p.p.m. NDGA or 0.5% DFMO, decreased the tumor incidence from 57.7 to 26.9%, or 16.7 or 20%, respectively (P < 0.05). NDGA alone (100 and 200 p.p.m.) slightly decreased the tumor incidence to 52.4 and 37%, respectively, although the difference was not statistically significant. DFMO alone did not show significant effects on tumor incidence. Inhibition of tumor formation by sulindac was correlated with lowered levels of PGE2. In conclusion, sulindac exerted its chemopreventive effect against the formation of EAC in the rat EGDA model possibly through its inhibition of Cox.
引用
收藏
页码:2095 / 2102
页数:8
相关论文
共 68 条
[1]  
AGARWAL R, 1991, DRUG METAB DISPOS, V19, P620
[2]   Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome c independent of COX-2 expression [J].
Aggarwal, S ;
Taneja, N ;
Lin, L ;
Orringer, MB ;
Rehemtulla, A ;
Beer, DG .
NEOPLASIA, 2000, 2 (04) :346-356
[3]   Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice [J].
Ansar, S ;
Iqbal, M ;
Athar, M .
CARCINOGENESIS, 1999, 20 (04) :599-606
[4]   Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions [J].
Avis, I ;
Hong, SH ;
Martínez, A ;
Moody, T ;
Choi, YH ;
Trepel, J ;
Das, R ;
Jett, M ;
Mulshine, JL .
FASEB JOURNAL, 2001, 15 (09) :2007-+
[5]   Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling [J].
Avis, IM ;
Jett, M ;
Boyle, T ;
Vos, MD ;
Moody, T ;
Treston, AM ;
Martinez, A ;
Mulshine, JL .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (03) :806-813
[6]   Fasting and postprandial polyamine concentrations in the human digestive lumen [J].
Benamouzig, R ;
Mahe, S ;
Luengo, C ;
Rautureau, J ;
Tome, D .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 65 (03) :766-770
[7]   CONTINUING CLIMB IN RATES OF ESOPHAGEAL ADENOCARCINOMA - AN UPDATE [J].
BLOT, WJ ;
DEVESA, SS ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (11) :1320-1320
[8]  
BRENNER DE, 2002, P AM ASSOC CANC RES, V43, pA5679
[9]  
BRENNER DE, 2002, P AM ASSOC CANC RES, V43, pA4989
[10]   Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study [J].
Brown, AP ;
Morrissey, RL ;
Crowell, JA ;
Levine, BS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) :475-483